Beigene Ltd (ADR) (BGNE) EPS Estimated At $-1.24; Honeywell International Has Decreased Abbott Lab (ABT) Stake

October 30, 2017 - By Marie Mckinney

Analysts expect Beigene Ltd (ADR) (NASDAQ:BGNE) to report $-1.24 EPS on November, 9.They anticipate $0.16 EPS change or 14.81% from last quarter’s $-1.08 EPS. After having $-1.52 EPS previously, Beigene Ltd (ADR)’s analysts see -18.42% EPS growth. About 16,630 shares traded. Beigene Ltd (ADR) (NASDAQ:BGNE) has risen 36.36% since October 30, 2016 and is uptrending. It has outperformed by 19.66% the S&P500.

Honeywell International Inc decreased Abbott Lab (ABT) stake by 34.67% reported in 2017Q2 SEC filing. Honeywell International Inc sold 277,830 shares as Abbott Lab (ABT)’s stock declined 3.42%. The Honeywell International Inc holds 523,596 shares with $25.45M value, down from 801,426 last quarter. Abbott Lab now has $95.42B valuation. The stock declined 0.79% or $0.44 reaching $54.92 per share. About 317,184 shares traded. Abbott Laboratories (NYSE:ABT) has risen 15.90% since October 30, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The company has market cap of $3.61 billion. The Firm is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It currently has negative earnings. The Firm had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Honeywell International Inc increased Anadarko Petro Corp (NYSE:APC) stake by 70,000 shares to 384,100 valued at $17.42M in 2017Q2. It also upped Allergan Plc stake by 20,100 shares and now owns 168,130 shares. Kirby Corp (NYSE:KEX) was raised too.

Among 24 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. Abbott Laboratories had 87 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Abbott Laboratories (NYSE:ABT) earned “Hold” rating by BMO Capital Markets on Thursday, August 31. Barclays Capital maintained the shares of ABT in report on Thursday, September 28 with “Overweight” rating. The company was downgraded on Friday, January 29 by William Blair. Cowen & Co maintained it with “Buy” rating and $68.0 target in Wednesday, October 18 report. As per Thursday, April 28, the company rating was downgraded by Piper Jaffray. The stock of Abbott Laboratories (NYSE:ABT) has “Equal-Weight” rating given on Thursday, October 19 by Morgan Stanley. The stock has “Market Perform” rating by BMO Capital Markets on Tuesday, March 14. The rating was maintained by Stifel Nicolaus on Thursday, July 23 with “Buy”. The stock has “Buy” rating by Jefferies on Friday, June 16. As per Tuesday, March 15, the company rating was maintained by Jefferies.